Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer.

Maulard C, Richaud P, Droz JP, Jessueld D, Dufour-Esquerré F, Housset M

Cancer chemotherapy and pharmacology1 Jan 1995Cited by 34 (Europe PMC)

PMID7540120DOI10.1007/bf00685857PepBankPUB-07540120

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialEfficacy outcome
In hormone-refractory prostate cancer patients, performance status improved in 40% during lanreotide treatment.
In plain wordsIn patients with hormone-refractory prostate cancer, performance status improved in 40% during lanreotide treatment.
Peptide
Lanreotide
Outcome
Direction not reportedPerformance status
Study
n = 30
Outcome group
Exercise and physical function · Cancer
Studied dose
30 mg once a week · intramuscular injection · mean 12 weeks (range 2-60 weeks)As given in this study (human).
Measurements
Patients with improved performance status
40 % of patients
30 patients, lanreotide 30 mg weekly
Source sentences
Summary
The performance status and bone pain were improved in 40% and 35% of patients respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 30 patients with hormone-refractory prostate cancer were treated with a slow-release formulation of lanreotide.
Summary · context
Patients were treated with one intramuscular injection of 30 mg BIM 23014 once a week and were followed for prostate-specific antigen (PSA) level evolution until disease progression or WHO grade 3 or 4 toxicity and for survival. The patients were treated for a mean duration of 12 weeks (range, 2-60 weeks).
Report a problemFND-0754012001
02HumanNon-randomized trialEfficacy outcome
In hormone-refractory prostate cancer patients, bone pain improved in 35% during lanreotide treatment.
In plain wordsIn patients with hormone-refractory prostate cancer, bone pain improved in 35% during lanreotide treatment.
Peptide
Lanreotide
Outcome
Direction not reportedBone pain
Study
n = 30
Outcome group
Pain · Cancer
Studied dose
30 mg once a week · intramuscular injection · mean 12 weeks (range 2-60 weeks)As given in this study (human).
Measurements
Patients with improved bone pain
35 % of patients
30 patients, lanreotide 30 mg weekly
Source sentences
Summary
The performance status and bone pain were improved in 40% and 35% of patients respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 30 patients with hormone-refractory prostate cancer were treated with a slow-release formulation of lanreotide.
Summary · context
Patients were treated with one intramuscular injection of 30 mg BIM 23014 once a week and were followed for prostate-specific antigen (PSA) level evolution until disease progression or WHO grade 3 or 4 toxicity and for survival. The patients were treated for a mean duration of 12 weeks (range, 2-60 weeks).
Report a problemFND-0754012002
03HumanNon-randomized trialEfficacy outcome
During lanreotide treatment, 20% of hormone-refractory prostate cancer patients had PSA decreases of at least 50%.
In plain wordsIn patients with hormone-refractory prostate cancer, 20% had PSA decreases of at least 50% during lanreotide treatment.
Peptide
Lanreotide
Outcome
DecreasePSA response
Study
n = 30
Outcome group
Tumor growth · Cancer
Studied dose
30 mg once a week · intramuscular injection · mean 12 weeks (range 2-60 weeks)As given in this study (human).
Measurements
Patients with PSA decrease of at least 50%
20 % of patients
30 patients, lanreotide 30 mg weekly
Source sentences
Summary
In all, 20% of the patients had a decrease of > or = 50% in PSA levels and 16% showed a stabilization.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 30 patients with hormone-refractory prostate cancer were treated with a slow-release formulation of lanreotide.
Summary · context
Patients were treated with one intramuscular injection of 30 mg BIM 23014 once a week and were followed for prostate-specific antigen (PSA) level evolution until disease progression or WHO grade 3 or 4 toxicity and for survival. The patients were treated for a mean duration of 12 weeks (range, 2-60 weeks).
Report a problemFND-0754012003
04HumanNon-randomized trialEfficacy outcome
During lanreotide treatment, 16% of hormone-refractory prostate cancer patients showed PSA stabilization.
In plain wordsIn patients with hormone-refractory prostate cancer, 16% had stable PSA levels during lanreotide treatment.
Peptide
Lanreotide
Outcome
Not applicablePSA stabilization
Study
n = 30
Outcome group
Tumor growth · Cancer
Studied dose
30 mg once a week · intramuscular injection · mean 12 weeks (range 2-60 weeks)As given in this study (human).
Measurements
Patients with PSA stabilization
16 % of patients
30 patients, lanreotide 30 mg weekly
Source sentences
Summary
In all, 20% of the patients had a decrease of > or = 50% in PSA levels and 16% showed a stabilization.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 30 patients with hormone-refractory prostate cancer were treated with a slow-release formulation of lanreotide.
Summary · context
Patients were treated with one intramuscular injection of 30 mg BIM 23014 once a week and were followed for prostate-specific antigen (PSA) level evolution until disease progression or WHO grade 3 or 4 toxicity and for survival. The patients were treated for a mean duration of 12 weeks (range, 2-60 weeks).
Report a problemFND-0754012004
05HumanNon-randomized trialEfficacy outcome
In lanreotide-treated prostate cancer patients, one-year survival was 72%, including 89% in PSA responders and 64% in progressive disease.
In plain wordsIn patients with prostate cancer receiving lanreotide, one-year survival was 72% overall, 89% in PSA responders, and 64% in progressive disease.
Peptide
Lanreotide
Outcome
Not applicableOne-year survival
Study
n = 30
Outcome group
Mortality · Cancer
Studied dose
30 mg once a week · intramuscular injection · mean 12 weeks (range 2-60 weeks)As given in this study (human).
Measurements
One-year survival rate
72%
all patients
One-year survival rate
89%
PSA responders
One-year survival rate
64%
patients with progressive disease
Source sentences
Summary
The 1-year global survival rate was 72%, with the rate being 89% in the group of patients who were responders on PSA plasma level and 64% in patients with progressive disease.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 30 patients with hormone-refractory prostate cancer were treated with a slow-release formulation of lanreotide.
Summary · context
Patients were treated with one intramuscular injection of 30 mg BIM 23014 once a week and were followed for prostate-specific antigen (PSA) level evolution until disease progression or WHO grade 3 or 4 toxicity and for survival. The patients were treated for a mean duration of 12 weeks (range, 2-60 weeks).
Report a problemFND-0754012006
06HumanNon-randomized trialSafety outcome
In lanreotide-treated prostate cancer patients, toxicity was minor, with transient grade I digestive side effects in a few patients.
In plain wordsIn patients with prostate cancer receiving lanreotide, a few had transient grade I digestive side effects.
Peptide
Lanreotide
Outcome
Not applicableDigestive side effects
Study
n = 30
Outcome group
Gastrointestinal adverse events · Cancer
Studied dose
30 mg once a week · intramuscular injection · mean 12 weeks (range 2-60 weeks)As given in this study (human).
Source sentences
Summary
Toxicity was minor, with transient grade I digestive side effects being noted in a few patients.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 30 patients with hormone-refractory prostate cancer were treated with a slow-release formulation of lanreotide.
Summary · context
Patients were treated with one intramuscular injection of 30 mg BIM 23014 once a week and were followed for prostate-specific antigen (PSA) level evolution until disease progression or WHO grade 3 or 4 toxicity and for survival. The patients were treated for a mean duration of 12 weeks (range, 2-60 weeks).
Report a problemFND-0754012008
07HumanNon-randomized trialEfficacy outcome
In responding prostate cancer patients treated with lanreotide, response duration ranged from 16 to 60 weeks.
In plain wordsIn responding patients with prostate cancer receiving lanreotide, responses lasted 16 to 60 weeks.
Peptide
Lanreotide
Outcome
Not applicableResponse duration
Study
n: not reported in source
Outcome group
Tumor growth · Cancer
Studied dose
30 mg once a week · intramuscular injection · mean 12 weeks (range 2-60 weeks)As given in this study (human).
Measurements
Response duration
16 to 60 weeks
responding patients
Source sentences
Summary
The response duration ranged from 16 to 60 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 30 patients with hormone-refractory prostate cancer were treated with a slow-release formulation of lanreotide.
Summary · context
Patients were treated with one intramuscular injection of 30 mg BIM 23014 once a week and were followed for prostate-specific antigen (PSA) level evolution until disease progression or WHO grade 3 or 4 toxicity and for survival. The patients were treated for a mean duration of 12 weeks (range, 2-60 weeks).
Report a problemFND-0754012007
08HumanObservational studyOther
In lanreotide-treated prostate cancer patients, biological response correlated with clinical improvement.
In plain wordsIn patients with prostate cancer receiving lanreotide, biological response was linked to clinical improvement.
Peptide
Lanreotide
Outcome
Not applicableBiological and clinical response correlation
Study
n = 30
Outcome group
Tumor growth · Cancer
Studied dose
30 mg once a week · intramuscular injection · mean 12 weeks (range 2-60 weeks)As given in this study (human).
Source sentences
Summary
The biological response was correlated with clinical improvement.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 30 patients with hormone-refractory prostate cancer were treated with a slow-release formulation of lanreotide.
Summary · context
Patients were treated with one intramuscular injection of 30 mg BIM 23014 once a week and were followed for prostate-specific antigen (PSA) level evolution until disease progression or WHO grade 3 or 4 toxicity and for survival. The patients were treated for a mean duration of 12 weeks (range, 2-60 weeks).
Report a problemFND-0754012005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.